CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His), FITC-Labeled

CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His), FITC-Labeled is expressed in HEK293 mammalian cells with N-His tag. The predicted molecular weight is 24.6 kDa and the accession number is Q5QGZ9-2.

规格	价格/CNY		数量
100 μg	￥ 8,900	5日内发货
500 μg	￥ 23,700	5日内发货
1 mg	￥ 39,500	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 8,900

5日内发货

500 μg

￥ 23,700

5日内发货

1 mg

￥ 39,500

5日内发货

产品描述

种属	Human
表达系统	HEK293
标签	N-His
蛋白编号	Q5QGZ9-2
别名	DCAL-2, HECL, CLL-1, CLECSF7, CD371, CLEC12A, PRO34150, MICL, CLECSF11, CD303, DLEC, DCAL2, CLL1
蛋白构建	Recombinant FITC-Labeled Human CLEC12A/MICL/CLL-1 Protein is expressed from HEK293 with His tag at the N-Terminus. It contains His65-Ala265.[Accession \|Q5QGZ9-2]
蛋白纯度	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
分子量	The protein has a predicted MW of 24.6 kDa. Due to glycosylation, the protein migrates to 35-55 kDa based on Tris-Bis PAGE result.

内毒素	Less than 1EU per μg by the LAL method.
缓冲液	Supplied as 0.22μm filtered solution in PBS (pH 7.4).
存储	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
运输方式	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
研究背景	CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.